In vivopharmacodynamics of new-generation β-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-β-lactamase-producing Gram-negative bacteria is a research paper published in Journal of Antimicrobial Chemotherapy (2020). On theSindex it has a DataRank of 0. It has been cited 47 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Department of Health and Human Services
Grant: HHSN272201300019C
Wellcome Trust
Grant: WT 101999/Z/13/Z
Wellcome Trust
Grant: 101999/Z/13/Z
NIAID NIH HHS
Grant: HHSN272201300019I
Wellcome Trust
Grant: 101999
Development of Pan -beta-lactamase inhibitors (Pan-BLIs) with activity against both serine- and metallo-beta-lactamases, including SHV, CTX-M, KPC, OXA, VIM and NDM-1.
Venatorx Pharmaceuticals, Inc.
Wellcome Trust
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals